Joel A Sincavage
Supervisory Patent Examiner (ID: 11124, Phone: (571)272-2610 , Office: P/2910 )
Most Active Art Unit | 2911 |
Art Unit(s) | 2911, 2900, 2901, 2910 |
Total Applications | 4082 |
Issued Applications | 4006 |
Pending Applications | 1 |
Abandoned Applications | 75 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 17124337
[patent_doc_number] => 20210299105
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => SELECTIVE INHIBITION OF T FOLLICULAR HELPER CELLS FOR TREATMENT OF AUTOIMMUNE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/110023
[patent_app_country] => US
[patent_app_date] => 2020-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23223
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17110023
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/110023 | Selective inhibition of T Follicular Helper cells for treatment of autoimmune disorders | Dec 1, 2020 | Issued |
Array
(
[id] => 19166004
[patent_doc_number] => 11981894
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-14
[patent_title] => Antisense nucleic acids
[patent_app_type] => utility
[patent_app_number] => 16/950449
[patent_app_country] => US
[patent_app_date] => 2020-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 25
[patent_no_of_words] => 14724
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950449
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/950449 | Antisense nucleic acids | Nov 16, 2020 | Issued |
Array
(
[id] => 16885759
[patent_doc_number] => 20210171954
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/089854
[patent_app_country] => US
[patent_app_date] => 2020-11-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53248
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17089854
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/089854 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | Nov 4, 2020 | Issued |
Array
(
[id] => 16712249
[patent_doc_number] => 20210079396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => ANTI-CONNEXIN COMPOUNDS TARGETED TO CONNEXINS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/033278
[patent_app_country] => US
[patent_app_date] => 2020-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33708
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17033278
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/033278 | Anti-connexin compounds targeted to connexins and methods of use thereof | Sep 24, 2020 | Issued |
Array
(
[id] => 16598407
[patent_doc_number] => 20210024938
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-28
[patent_title] => SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER
[patent_app_type] => utility
[patent_app_number] => 17/027467
[patent_app_country] => US
[patent_app_date] => 2020-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14830
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17027467
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/027467 | Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer | Sep 20, 2020 | Issued |
Array
(
[id] => 16506177
[patent_doc_number] => 20200385433
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-10
[patent_title] => ALPHA-HEMOLYSIN VARIANTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/947959
[patent_app_country] => US
[patent_app_date] => 2020-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11003
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16947959
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/947959 | ALPHA-HEMOLYSIN VARIANTS AND USES THEREOF | Aug 24, 2020 | Pending |
Array
(
[id] => 19580086
[patent_doc_number] => 12146186
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-19
[patent_title] => HiC: method of identifying regulatory interactions between genomic loci
[patent_app_type] => utility
[patent_app_number] => 16/990543
[patent_app_country] => US
[patent_app_date] => 2020-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 55
[patent_figures_cnt] => 71
[patent_no_of_words] => 38746
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16990543
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/990543 | HiC: method of identifying regulatory interactions between genomic loci | Aug 10, 2020 | Issued |
Array
(
[id] => 17681173
[patent_doc_number] => 11365414
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-21
[patent_title] => Methods of inducing insulin production
[patent_app_type] => utility
[patent_app_number] => 16/990347
[patent_app_country] => US
[patent_app_date] => 2020-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 17
[patent_no_of_words] => 28032
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16990347
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/990347 | Methods of inducing insulin production | Aug 10, 2020 | Issued |
Array
(
[id] => 16569087
[patent_doc_number] => 20210008093
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS
[patent_app_type] => utility
[patent_app_number] => 16/988427
[patent_app_country] => US
[patent_app_date] => 2020-08-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25807
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988427
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/988427 | Methods and compositions for the activation of gamma-delta T-cells | Aug 6, 2020 | Issued |
Array
(
[id] => 16688700
[patent_doc_number] => 20210071176
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => COMPOSITIONS FOR MODULATING TAU EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 16/986770
[patent_app_country] => US
[patent_app_date] => 2020-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53677
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16986770
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/986770 | Compositions for modulating Tau expression | Aug 5, 2020 | Issued |
Array
(
[id] => 16628991
[patent_doc_number] => 20210047644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-18
[patent_title] => COMBINATION VECTORS AND METHODS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 16/943800
[patent_app_country] => US
[patent_app_date] => 2020-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19484
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16943800
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/943800 | Combination vectors and methods for treating cancer | Jul 29, 2020 | Issued |
Array
(
[id] => 16655986
[patent_doc_number] => 20210052622
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-25
[patent_title] => DEFIBROTIDE FOR USE IN PROPHYLAXIS AND/OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD)
[patent_app_type] => utility
[patent_app_number] => 16/942328
[patent_app_country] => US
[patent_app_date] => 2020-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4582
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16942328
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/942328 | DEFIBROTIDE FOR USE IN PROPHYLAXIS AND/OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) | Jul 28, 2020 | Abandoned |
Array
(
[id] => 17845131
[patent_doc_number] => 11434487
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-06
[patent_title] => Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/939119
[patent_app_country] => US
[patent_app_date] => 2020-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56039
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16939119
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/939119 | Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof | Jul 26, 2020 | Issued |
Array
(
[id] => 16422254
[patent_doc_number] => 20200347452
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-05
[patent_title] => METHOD FOR EVALUATING STATE OF UNDIFFERENTIATED CELL AND UTILIZATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/939193
[patent_app_country] => US
[patent_app_date] => 2020-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8945
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16939193
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/939193 | METHOD FOR EVALUATING STATE OF UNDIFFERENTIATED CELL AND UTILIZATION THEREOF | Jul 26, 2020 | Abandoned |
Array
(
[id] => 18029139
[patent_doc_number] => 11512314
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-29
[patent_title] => Amphiphilic polynucleotides
[patent_app_type] => utility
[patent_app_number] => 16/927982
[patent_app_country] => US
[patent_app_date] => 2020-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 48
[patent_figures_cnt] => 48
[patent_no_of_words] => 13960
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16927982
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/927982 | Amphiphilic polynucleotides | Jul 12, 2020 | Issued |
Array
(
[id] => 16513226
[patent_doc_number] => 20200392484
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => COMPOSITIONS AND METHODS FOR IDENTIFYING POLYNUCLEOTIDES OF INTEREST
[patent_app_type] => utility
[patent_app_number] => 16/909979
[patent_app_country] => US
[patent_app_date] => 2020-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23228
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16909979
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/909979 | Compositions and methods for identifying polynucleotides of interest | Jun 22, 2020 | Issued |
Array
(
[id] => 16901144
[patent_doc_number] => 20210180060
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
[patent_app_type] => utility
[patent_app_number] => 16/899802
[patent_app_country] => US
[patent_app_date] => 2020-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25388
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16899802
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/899802 | MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD | Jun 11, 2020 | Abandoned |
Array
(
[id] => 16570943
[patent_doc_number] => 20210009949
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => MODELS OF TAUOPATHY
[patent_app_type] => utility
[patent_app_number] => 16/900432
[patent_app_country] => US
[patent_app_date] => 2020-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45502
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16900432
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/900432 | Models of tauopathy | Jun 11, 2020 | Issued |
Array
(
[id] => 17997863
[patent_doc_number] => 11498957
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-15
[patent_title] => Composition and method for inhibiting amyloid b accumulation and/or aggregation
[patent_app_type] => utility
[patent_app_number] => 16/898187
[patent_app_country] => US
[patent_app_date] => 2020-06-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 34
[patent_no_of_words] => 15357
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16898187
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/898187 | Composition and method for inhibiting amyloid b accumulation and/or aggregation | Jun 9, 2020 | Issued |
Array
(
[id] => 16506471
[patent_doc_number] => 20200385727
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-10
[patent_title] => ANTISENSE OLIGONUCLEOTIDES TARGETING ATXN3
[patent_app_type] => utility
[patent_app_number] => 16/946118
[patent_app_country] => US
[patent_app_date] => 2020-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16946118
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/946118 | Antisense oligonucleotides targeting ATXN3 | Jun 4, 2020 | Issued |